key: cord-0713536-ek7clbp9
authors: Nagrani, Prateek; Jindal, Rashmi; Goyal, Dikshita
title: Onset/flare of psoriasis following the ChAdOx1 nCoV‐19 Corona virus vaccine (Oxford‐AstraZeneca/Covishield): Report of two cases
date: 2021-08-10
journal: Dermatol Ther
DOI: 10.1111/dth.15085
sha: 276ce182b046e2fda1a306295c3428fef4136c51
doc_id: 713536
cord_uid: ek7clbp9

nan

vaccine is purported to be generally safe; but is associated with a low risk of thrombocytopenia and central venous thromboembolism. 2 So far, a single case of suspected delayed inflammatory cutaneous reaction after the Oxford-AstraZeneca vaccine has been reported in a 68-year-old woman with localized scleroderma. Her rash started 3 days postvaccination as pruritic, erythematous papules initially limited to her morphea lesion and later spread to the whole body. 3 Patients on immunosuppressive therapy were excluded from trial cohorts of Covid-19 vaccines, and as many patients of psoriasis receive immunosuppressive drugs, they must have been underrepresented in these trials. 4 Hence accumulation of data regarding the propensity of different Covid-19 vaccines to aggravate or precipitate psoriasis might help update the current guidelines. Herein we report two cases of psoriasis exacerbation following administration of Covishield vaccine.

The first case is of a 56-year-old lady. She was a known case of psoriasis and was in remission for 6 months, maintaining on emollients. One Thus, the potential of Covid vaccination acting as a trigger for psoriasis exacerbation cannot be denied. However, since the benefits overweigh the risks, all patients must receive the vaccine.

The authors declare there is no potential conflict of interest.

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Ministry of Health and Family Welfare, Government of India. COVID-19 vaccine faqs

Serum Institute of India. Covishield faqs

Cutaneous adverse effects of the available COVID-19 vaccines

ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant): Covishield product monograph

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial

A generalized pustular psoriasis flare after CoronaVac COVID-19 vaccination: case report

National survey of psoriasis flares after 2009 monovalent H1N1/seasonal vaccines

The environment and disease: association or causation